Foresite Capital Management IV

Latest statistics and disclosures from Foresite Capital Management IV's latest quarterly 13F-HR filing:

  • Top 5 stock holdings are PHVS, CYTK, LYEL, MAZE, RLAY, and represent 94.24% of Foresite Capital Management IV's stock portfolio.
  • Added to shares of these 1 stock: ALEC (+$6.1M).
  • Started 1 new stock position in ALEC.
  • Foresite Capital Management IV was a net buyer of stock by $6.1M.
  • Foresite Capital Management IV has $230M in assets under management (AUM), dropping by 25.79%.
  • Central Index Key (CIK): 0001704132

Tip: Access up to 7 years of quarterly data

Positions held by Foresite Capital Management IV consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Portfolio Holdings for Foresite Capital Management IV

Foresite Capital Management IV holds 7 positions in its portfolio as reported in the December 2025 quarterly 13F filing

Company (Ticker) Portfolio Weight Valued At Change in Shares Share Count Share Price
Pharvaris N V (PHVS) 57.7 $133M 4.8M 27.75
 View chart
Cytokinetics (CYTK) 12.7 $29M 458k 63.54
 View chart
Lyell Immunopharma (LYEL) 10.7 $25M 800k 30.78
 View chart
Maze Therapeatics (MAZE) 9.4 $22M 523k 41.43
 View chart
Relay Therapeutics (RLAY) 3.7 $8.5M 1.0M 8.46
 View chart
Xenon Pharmaceuticals (XENE) 3.1 $7.2M 160k 44.82
 View chart
Alector (ALEC) 2.6 $6.1M NEW 3.9M 1.56
 View chart

Past Filings by Foresite Capital Management IV

SEC 13F filings are viewable for Foresite Capital Management IV going back to 2017

View all past filings